Navigation Links
Angeion Corporation Reports First Quarter Fiscal Year 2012 Operating Results

SAINT PAUL, Minn., Feb. 28, 2012 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) today reported financial results for its first quarter fiscal 2012 ended January 31, 2012.

First Quarter Highlights:

  • Revenues of $7.1 million, comparable to the first quarter of 2011;
  • Service revenue improved 19% to $1.1 million, compared to $909,000 in last year's first quarter;
  • GPO (group purchasing organization) revenue during the first quarter increased 321% to $1.4 million, compared to $332,000 in the comparable quarter;
  • Recurring revenue in the first quarter increased 14% to $3.9 million and accounted for approximately 55% of total revenue in the quarter;
  • Gross margin for the first quarter remained solid at 56.4%;
  • Domestic sales increased to $5.7 million, a 10% increase over the prior year's first quarter;
  • Strong balance sheet with $9.2 million in cash and investments, over $13 million of working capital and no long-term debt; and
  • Addition of RTD™ (Real-Time-Diffusion™) MultiGas Technology™ to our product family.

  • Angeion reported revenue of $7.1 million compared to $7.1 million in the first quarter of fiscal 2011. For the first quarter, domestic sales increased 10% to $5.7 million, compared to $5.2 million in the previous year's first quarter and international sales decreased by 26% to $1.4 million, versus $1.9 million in last year's comparable first quarter. During the first quarter, equipment, supplies and accessories sales decreased by 2.7% to $6.0 million, compared to $6.1 million during last year's period. Service revenue increased 19% to $1.1 million, versus $909,000 in last year's first quarter.   Angeion reported net loss of $249,000, or ($0.07) per diluted share, versus net loss of $324,000, or ($0.09) per diluted share, in the comparable quarter last year.

    Gross margin for the quarter remained firm at 56.4% compared to the first quarter of fiscal year 2011. General and administrative expenses in the first quarter of fiscal 2012 decreased 14.9% primarily due to the absence of severance and related one-time expenses. Management will continue to examine operating expenses going forward to ensure they remain at reasonable levels. Sales and marketing expenses increased 1.2% compared to the first quarter of fiscal 2011 while research and development costs increased 13.8%. As management disclosed in the fourth quarter, the Company has made a strategic decision to dedicate additional resources to advance software and hardware development initiatives to enhance current product offerings and develop future new products.

    Gregg O. Lehman, Ph.D., president and chief executive officer of Angeion Corporation commented, "We are pleased with the measurable progress achieved in the past two quarters by refocusing the Company on our new strategy and installing more disciplined business processes. The top-line and bottom-line results of the first fiscal quarter of 2012 are generally in line with our internal expectations.  Domestic sales for the quarter were up 10% despite the fact our fiscal first quarters are generally most affected by the inherent seasonality in the medical device business. Our strategic decision to focus on developing GPO partnerships continues to pay dividends, as the GPO sales channel delivered a strong quarter with revenues more than three times that of the first quarter of fiscal 2011 and accounted for 20% of total sales for the quarter. Service revenues increased 19% in the first quarter as our direct sales force continued to execute on our initiative to expand service revenues, and in turn, recurring revenues, which accounted for 55% of the quarter's total revenues."

    "Outside the U.S. market," continued Dr. Lehman, "economic conditions in Europe continue to be very challenging and substantially impacted revenues in the first quarter of fiscal 2012 with a 26% decrease in total international sales from last year's first quarter. We continue to believe that international markets will be a significant contributor in the coming years and we are dedicated to strengthening our distribution capabilities in those markets as economic conditions improve."

    Dr. Lehman continued, "We are committed to developing new products and refreshing our existing product lines so that they can be produced in the most cost-efficient manner possible, leading to enhanced margins, and giving us the ability to enter into new markets. We are pleased to have recently introduced to our customers worldwide our new RTD™ (Real-Time Diffusion™) MultiGas Technology™. This proprietary technology platform and real-time sensor quality assurance provides accurate and immediate results, and eliminates the need for repeat tests. The addition of RTD to our product family will provide access to markets from which Angeion may have been previously excluded. This ability to better serve our existing markets and enter new markets represents the new product development model that we expect to execute. We are committed to becoming an industry leader in efficient manufacturing practices and innovative diagnostic solutions."

    "As we move through fiscal year 2012, we will commence a number of initiatives, including rebranding the company and leveraging the MedGraphics name to more fully capitalize on the favorable brand equity that we have developed over the years. We look to solidify the identity of the company with that of our products in the minds of our customers and the national investment community as well. Our strong working capital position will facilitate plans to expand and advance our product lines via in-house development as well as participating in joint venture opportunities, and opportunistic and strategic acquisitions. With the business on a more stable footing, we will now move ahead to reconfigure the company for future growth. We believe there are outstanding opportunities in new markets such as primary care, home monitoring and telemedicine that can benefit from MedGraphics technology."

    Balance Sheet
    As of January 31, 2012, the Company ended the first quarter fiscal 2012 with cash, equivalents and short term investments totaling $9.2 million, working capital of $13.3 million, no long-term debt and shareholders' equity of $14.2 million. For the first quarter, the Company repurchased a total of 1,000 shares of Angeion common stock in the open market for an average price of $4.98 per share. Under the current stock repurchase program, the Company has the authorization to purchase an additional $2.8 million worth of stock and is prepared to take advantage of opportunistic buying situations.

    Conference Call
    The Company has scheduled a conference call for February 28, 2012 at 5:00 p.m. ET to discuss its financial results for the first quarter fiscal 2012.

    Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or listen via a live Internet webcast on the Company's website at A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code 10010101, through March 5, 2012. A webcast replay of the conference call will be accessible on the Company's website at for 90 days.

    About Angeion Corporation
    Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics ( and New Leaf ( brand names. These cardiorespiratory product lines provide solutions for disease detection, integrated care, and wellness across the entire spectrum of health – whether managing chronic illness, promoting fitness, or training for the Olympics. The Company's products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians' offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit

    Forward Looking Statements
    Press releases and other statements by Angeion may contain forward-looking statements about Angeion's future financial results and business prospects that by their nature involve substantial risks and uncertainties.  You can identify these statements by the use of words such as "anticipate," "believe," "estimate," "expect," "project," "intend," "plan," "will," "target," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects.  Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinic, and office markets; (3) remaining as a qualified provider for large group purchasing organizations, thereby ensuring continued access to our market and efficiently increasing our sales potential to expanded numbers of companies using these buying groups; (4) any changes in the patterns of medical reimbursement that may result from national healthcare reform; (5) our ability to successfully operate our business, including successfully converting our increasing research and development expenditures into new and improved cardiorespiratory diagnostic products and services and selling these products and services under the MedGraphics and New Leaf brand names into existing and new markets; (6) our ability to complete our software development initiatives and migrate our MedGraphics and New Leaf platforms to a next generation technology; (7) our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (8) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (9) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (10) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (11) our ability to defend our existing intellectual property and obtain protection for intellectual property we develop in the future; (12) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; (13) our dependence on third-party vendors and (14) the ability of new members of our senior management to make a successful transition into their new roles and for all members of senior management to ultimately develop and implement a strategic plan.  These and other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2011.Contact:

    Robert M. Wolf

    Joe Dorame, Robert Blum, Joe DiazAngeion Corporation

    Lytham Partners, LLCChief Financial Officer

    (602) 889-9700(651) 766-4874

    angn@lythampartners.comANGEION CORPORATION AND SUBSIDIARIESConsolidated Balance SheetsJanuary 31, 2012 and October 31, 2011(In thousands except share and per share data)January 31,2012October 31,2011ASSETS(Unaudited)Current Assets:Cash and cash equivalents$   8,674$   8,461Short-term investments481723Accounts receivable, net of allowance for doubtful accounts of $93
    and $96, respectively4,8985,958Inventories, net of obsolescence reserve of $478 and $431,
    respectively4,1223,750Prepaid expenses and other current assets 198235Total Current Assets18,37319,127Property and equipment, net of accumulated depreciation of $3,798
    and $3,735, respectively423444Intangible assets, net1,2901,201Total Assets$  20,086$  20,772LIABILITIES AND SHAREHOLDERS' EQUITYCurrent Liabilities:Accounts payable$   1,833$   2,022Employee compensation1,2791,481Deferred income1,5911,771Warranty reserve122141Other current liabilities and accrued expenses230221Total Current Liabilities5,0555,636Long-term Liabilities:Long-term deferred income and other814817Total Liabilities5,8696,453Commitments and Contingencies--Shareholders' Equity:Common Stock, $0.10 par value, authorized 25,000,000 shares,
    3,961,742 and 3,905,648 shares issued and 3,797,800 and
    3,778,796 shares outstanding in 2012 and 2011, respectively380378Additional paid-in capital20,76820,622Accumulated deficit(6,932)(6,683)Accumulated other comprehensive income12Total Shareholders' Equity14,21714,319Total Liabilities and Shareholders' Equity$  20,086$  20,772ANGEION CORPORATION AND SUBSIDIARIESConsolidated Statements of Operations(Unaudited, in thousands except per share data)Three Months EndedJanuary 31,20122011RevenuesEquipment, supplies and accessories
    revenues$  5,976$  6,144Service revenues1,0839097,0597,053Cost of revenuesCost of equipment, supplies and accessories
    revenues2,7272,716Cost of service revenues3503563,0773,072Gross margin3,9823,981Operating expenses:Selling and marketing2,0712,047General and administrative1,1831,390Research and development866761Amortization of intangibles1081054,2284,303Operating loss(246)(322)Interest income48Loss before taxes(242)(314)Provision for taxes710Net loss$   (249)$   (324)Loss per share:Basic$   (0.07)$   (0.09)Diluted$   (0.07)$   (0.09)Weighted average common shares outstanding:Basic3,7803,754Diluted3,7803,754ANGEION CORPORATION AND SUBSIDIARIESConsolidated Statements of Cash Flows(Unaudited, in thousands)Three Months EndedJanuary 31,20122011Cash flows from operating activities:Net loss$
    (324)Adjustments to reconcile net loss to net cash provided by operating
    activities:Depreciation6464Amortization108105Stock-based compensation13734Decrease in allowance for doubtful accounts(3)(10)Increase (decrease) in inventory obsolescence reserve47(25)Loss on disposal of equipment-22Change in operating assets and liabilities:Accounts receivable1,063480Inventories(419)(45)Prepaid expenses and other current assets3795Accounts payable(189)(83)Employee compensation(202)131Deferred income(218)(61)Warranty reserve(19)(35)Other current liabilities and accrued expenses9(88)Net cash provided by operating activities166260Cash flows from investing activities:Sales of investments2411,239Purchase of property and equipment and intangible assets(240)(173)Net cash provided by investing activities11,066Cash flows from financing activities:Proceeds from issuance of common stock under employee stock
    purchase plan1112Proceeds from the exercise of stock options4048Repurchase of common stock(5)-Net cash provided by financing activities4660Net increase in cash and cash equivalents2131,386Cash and cash equivalents at beginning of period8,4616,943Cash and cash equivalents at end of period$

    SOURCE Angeion Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Angeion Corporation to Report Third Quarter Fiscal Year 2011 Financial Results on Thursday, September 1, 2011
    2. Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results
    3. Angeion Corporation to Report Fourth Quarter and Fiscal Year 2011 Financial Results on Friday, December 16, 2011
    4. Angeion Corporation Reports Fourth Quarter and Fiscal Year 2011 Operating Results
    5. Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
    6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
    7. CEL-SCI Corporation Releases Letter to Shareholders
    8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
    9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
    10. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
    11. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
    Post Your Comments:
    (Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
    (Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
    (Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
    (Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
    (Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
    Breaking Medicine News(10 mins):